Prolonged Administration Enhances the Renoprotective Effect of Pentoxifylline via Anti-Inflammatory Activity in Streptozotocin-Induced Diabetic Nephropathy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Kum Hyun | - |
dc.contributor.author | Han, Sang Youb | - |
dc.contributor.author | Kim, Han Seong | - |
dc.contributor.author | Kang, Young Sun | - |
dc.contributor.author | Cha, Dae Ryong | - |
dc.date.available | 2020-11-03T05:51:12Z | - |
dc.date.issued | 2010-06 | - |
dc.identifier.issn | 0360-3997 | - |
dc.identifier.issn | 1573-2576 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/14835 | - |
dc.description.abstract | The beneficial effects of pentoxifylline (PTX), which has an anti-inflammatory and renoprotective effect in diabetic nephropathy, are not completely understood. This study investigates whether prolonged administration of PTX (40 mg/kg, per oral) is effective in streptozotocin-induced diabetic nephropathy. The amount of urinary protein was higher in the diabetic rats than in the control rats. The amount remained unchanged after 4 weeks and decreased after 8 weeks of PTX treatment. Accumulation of monocyte chemoattractant peptide-1 (MCP-1) and mouse monoclonal anti-monocyte/macrophage antibody (ED-1) positive cells was higher in untreated diabetic rats than in the control rats. PTX administration ameliorated the urinary MCP-1 excretion and interstitial infiltration of ED-1 positive cells at 4 weeks. Further, in diabetic rats, administration of PTX for 4 weeks inhibited the renal inflammatory reaction, and when administration for 8 weeks, it prevented proteinuria. These findings support the hypothesis that prolonged administration enhances the protective effects of PTX. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER/PLENUM PUBLISHERS | - |
dc.title | Prolonged Administration Enhances the Renoprotective Effect of Pentoxifylline via Anti-Inflammatory Activity in Streptozotocin-Induced Diabetic Nephropathy | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1007/s10753-009-9167-6 | - |
dc.identifier.scopusid | 2-s2.0-77954691093 | - |
dc.identifier.wosid | 000276870900001 | - |
dc.identifier.bibliographicCitation | INFLAMMATION, v.33, no.3, pp 137 - 143 | - |
dc.citation.title | INFLAMMATION | - |
dc.citation.volume | 33 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 137 | - |
dc.citation.endPage | 143 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | MONOCYTE CHEMOATTRACTANT PROTEIN-1 | - |
dc.subject.keywordPlus | CONVERTING ENZYME-INHIBITION | - |
dc.subject.keywordPlus | TUMOR-NECROSIS-FACTOR | - |
dc.subject.keywordPlus | URINARY PROTEIN | - |
dc.subject.keywordPlus | GENE-THERAPY | - |
dc.subject.keywordPlus | RENAL INJURY | - |
dc.subject.keywordPlus | SHORT-TERM | - |
dc.subject.keywordPlus | RATS | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | COMPLICATIONS | - |
dc.subject.keywordAuthor | diabetic nephropathy | - |
dc.subject.keywordAuthor | inflammation | - |
dc.subject.keywordAuthor | pentoxifylline | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.